$2.87
$2.58
$52.40
$1.10
$17.8M
-92.47%
This is a preview of the full version of Prosperse
BioVie received FDA authorization to evaluate its drug bezisterim in a Phase 2 trial for treating neurological symptoms associated with long COVID. The trial is supported by a $12.6 million grant from the U.S. Department of Defense.
N/A
Sep 3, 2024
BioVie presented clinical data showing that its drug candidate bezisterim may have the ability to modulate DNA methylation, reduce inflammation, and impact the biological aging process. The data suggests bezisterim could have potential in treating various neurodegenerative disorders.
N/A
Aug 27, 2024
Date: Oct 25, 2024
Date: Oct 25, 2024
Date: Oct 25, 2024
Date: Oct 24, 2024
Date: Oct 24, 2024